Mediwound Ltd (MDWD) Q1 2026 Earnings Call Transcript

Why It Matters

The results highlight liquidity strength despite lower sales, and underscore that future growth hinges on regulatory approvals and BARDA funding for both NexoBrid and the late‑stage EscharEx program.

Key Takeaways

• Q1 revenue fell to $1.9M, down from $5.8M.
• EscharEx Phase III VALUE study targets 216 patients by 2026.
• New facility increases NexoBrid capacity sixfold, pending approval.
• B. Braun joins as seventh partner for EscharEx program.
• Cash balance rose to $53.6M after $33.5M equity raise.

Pulse Analysis

MedWound’s Q1 financials illustrate the volatility that can arise from macro‑policy disruptions. Revenue contracted to $1.9 million as the U.S. government shutdown postponed key BARDA contracts, yet the company’s balance sheet strengthened, ending the year with $53.6 million in cash after a $30 million registered direct offering and $3.5 million from warrant exercises. Operating losses widened, but the improved cash position provides a runway for continued R&D investment and the scaling of its manufacturing footprint.

On the clinical front, the company is accelerating its EscharEx pipeline. The Phase III VALUE trial for venous leg ulcers is on track to enroll 216 patients by year‑end 2026, and the program now spans diabetic foot and pressure ulcer indications, aligning with both FDA and EMA guidance. Strategic collaborations have deepened, with B. Braun becoming the seventh partner, supplying Prontosan cleanser for the DFU study, while existing ties with Coloplast, ConvaTec, and others reinforce market credibility. Simultaneously, the newly operational manufacturing site multiplies NexoBrid output sixfold, positioning the firm to meet anticipated surge in burn‑care demand once regulatory clearance is secured.

Looking ahead, MedWound reaffirmed its 2026‑2028 revenue guidance, forecasting $24‑$26 million for 2026 and up to $55 million by 2028, contingent on BARDA and Department of War funding and successful regulatory approvals. The expanded capacity, coupled with real‑world evidence from military deployments, suggests a sizable addressable market for both NexoBrid and the forthcoming EscharEx commercial launch. If the company navigates the pending approvals, it could translate its infrastructure investments into sustained top‑line growth and solidify its position in the advanced wound‑care sector.